I appreciate you Suzuki and don't particularly disagree with your points above.
One thing I believe we are in violent agreement about is launching AVR's TAVR (even with an in-house sales team) has much better economics than selling ADAPT tissue, expensive (but good) sales ppl should pay for themselves in no time.
I'm looking forward to seeing the FDA study / approval progress, and I'd love to see a solid plan (budget/cash burn) until AVR can get FDA approval. (I also hope they go for both SAVR and TAVR approval).
GLTAH
I appreciate you Suzuki and don't particularly disagree...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.40 |
Change
-0.290(1.55%) |
Mkt cap ! $353.6M | |||
| Open | High | Low | Value | Volume |
| $18.70 | $18.70 | $18.20 | $96.48K | 5.231K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $18.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.40 | 52 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |